Mode
Text Size
Log in / Sign up
Phase 3 N=17 Basic Science

Neuroimaging Study of Dexmedetomidine-Induced Analgesia

Analgesia · Anesthesia

Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: CSF Flow Measured in Hz — -15 Hz

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Dexmedetomidine (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
May 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
CSF Flow Measured in Hz
-15

Summary

Neuroimaging data will be collected for patients that are given low doses of dexmedetomidine in order to understand its analgesic effects.

Eligibility Criteria

Inclusion Criteria

  • Between the ages of 18 to 45
  • Normal body weight and habitus, BMI ≤ 30
  • Non-smoker
  • American Society of Anesthesiologists (ASA) physical status classification P1
  • Active health insurance coverage
  • Fully vaccinated against COVID-19

Exclusion Criteria

  • Cardiovascular: myocardial infarction, coronary artery disease, peripheral vascular disease, arrhythmia, congestive heart failure, valvular disease, hypertension
  • Respiratory: bronchitis, chronic obstructive pulmonary disease, smoking, shortness of breath
  • Hepatic: hepatitis, jaundice, ascites
  • Neurologic: seizure, stroke, positive neurologic findings on neurologic examination, multiple sclerosis, Meniere's disease, Parkinson's disease, neuropathy, peripheral stenosis
  • Gastrointestinal: esophageal reflux, hiatal hernia, ulcer
  • Endocrine: diabetes, thyroid disease
  • Renal: acute or chronic severe renal insufficiency
  • Hematologic: blood dyscrasias, anemia, coagulopathies, on anticoagulant therapy
  • Musculoskeletal: prior surgery or trauma to head neck or face, arthritis, personal or family history of malignant hyperthermia
  • Psychiatric: history or treatment for an active psychiatric problem, depression
  • Reproductive: pregnancy, breast-feeding
  • Medications: regular use of prescription and non-prescription medications expected to affect CNS function, St. John's Wort
  • Allergies: dexmedetomidine, ondansetron, glycopyrrolate, phenylephrine
  • Dermatologic: ulcerative skin conditions or other dermatologic conditions which could interfere with blood pressure cuff placement.
  • MRI reasons for exclusion: History of head trauma, surgical aneurysm clips, cardiac pacemaker, prosthetic heart valve, neurostimulator, implanted pumps, cochlear implants, metal rods, plates, or screws, intrauterine device, hearing aid, dentures, metal injury to eyes, metallic tattoos anywhere on the body or near the eye.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04656470). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search